UGT1A1*28 is Associated with Decreased Systemic Exposure of Atorvastatin Lactone

Atorvastatin Metabolite Measurements as a Diagnostic Tool for Statin-Induced Myopathy

(2012) Ine B. Skottheim et al.   Molecular Diagnosis & Therapy

The UGT1A3*2 polymorphism affects atorvastatin lactonization and lipid-lowering effect in healthy volunteers

(2012) Sung Kweon Cho et al.   Pharmacogenetics and Genomics

Risk Factors and Drug Interactions Predisposing to Statin-Induced Myopathy

(2010) Yiannis S. Chatzizisis et al.   DRUG SAFETY

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials

(2010)   LANCET

UDP-Glucuronosyltransferase (UGT) Polymorphisms Affect Atorvastatin Lactonization In Vitro and In Vivo

(2009) S Riedmaier et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

The SLCO1B1*5Genetic Variant Is Associated With Statin-Induced Side Effects

(2009) Deepak Voora et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Statin induced myotoxicity: The lactone forms are more potent than the acid forms in human skeletal muscle cells in vitro

(2008) Ine Blankenberg Skottheim et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

SLCO1B1Variants and Statin-Induced Myopathy — A Genomewide Study

(2008)   NEW ENGLAND JOURNAL OF MEDICINE